TEL AVIV, Israel, April 3, 2018 /PRNewswire/ --
The 17th annual MIXiii-BIOMED 2018, the premier
Previous successful conferences hosted over 6,000 industry players, scientists, engineers and investors including more than 1,000 attendees from over 45 countries. As in previous years, hundreds of Israeli life science companies will present and exhibit their products, services and technologies.
Co-Chaired by Ruti Alon, Founder and CEO of Medstrada, Ora Dar, PhD, The Israel Innovation Authority and Nissim Darvish, MD, PhD, Senior Managing Director OrbiMed, the conference will explore and aim to fuel the innovations and trends that are shaping the future of healthcare systems and life science. It will include the nine following tracks:
Among the conference's speakers are:
Arie S. Belldegrun MD, Founder & CEO, Kite Pharma
Paul R. Bondi, Senior Vice President, Head of Business Development, Bristol-Myers Squibb
Troy Cox, Chief Executive Officer, Foundation Medicine
Bruce R. Rosengard, MD, Chief Medical Science & Technology Officer,
Johnson & Johnson Medical Devices Companies
Francois Maisonrouge, Senior Managing Director, Evercore Partners
Aharon Aharon, CEO, Israel Innovation Authority
Tauhid Ali, PhD, Vice President and Head of TAK-celerator, Takeda
Gil Bar-Nahum, PhD, Managing Director, Jefferies International, London, UK
David Fenstermacher, PhD, Vice President R&D-Bioinformatics, Medimmune
Chris Kaster, Vice President, Business Development, Venture Capital Investing, Boston Scientific
Hartmuth Kolb, PhD, Head of Neuroscience Biomarkers, Janssen Research & Development
Walter Kowtoniuk, PhD, Principle, Third Rock Ventures
Daphna Laifenfeld, PhD, Head, Personalized Medicine & Diagnostics, Teva Pharmaceuticals
Michael Martin, PhD, Global Head, Takeda Ventures, Inc.
Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers
David Neustaedter, Vice President, Venture Capital Medtronic
Prof. David Sidransky, MD, Johns Hopkins School of Medicine and Co-Founder and General Partner, Israel Biotech Fund
Michal Silverberg, Managing Director, Novartis Venture Fund
Stephen Squinto, PhD, Venture Partner, Orbimed Healthcare Fund Management
Anand Subramony, PhD, Vice President, Novel Product Technologies,
Miro Venturi, PhD, Global Head, Diagnostics Biomarkers, F. Hoffmann-La Roche Ltd.
Zeev Zehavi, Vice President of Venture Investments, Johnson & Johnson Innovation - JJDC, Inc.
For the conference's preliminary program
Contact: Tsipi Haitovsky Global Media Liaison MIXiii-BIOMED Email: firstname.lastname@example.org Tel: +972-52-598-9892
Subscribe to our Free Newsletters!
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...View All